Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -10.66%6 EV-to-FCF is -19.59 as of Aug. 01, 2026. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 345 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 289854.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Veraxa Biotech Holding AG's Enterprise Value is $250.95 Mil.
Veraxa Biotech Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.81 Mil. Therefore, Veraxa Biotech Holding AG's EV-to-FCF for today is -19.59.
The historical rank and industry rank for Veraxa Biotech Holding AG's EV-to-FCF or its related term are showing as below:
VRXA'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.59 Med: 0 Max: 0
Current: -19.59
VRXA's EV-to-FCF is ranked worse than 100% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs VRXA: -19.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veraxa Biotech Holding AG (NAS:VRXA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veraxa Biotech Holding AG's PE Ratio (TTM) for today is calculated as:
Veraxa Biotech Holding AG's share price for today is $1.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veraxa Biotech Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.584.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Veraxa Biotech Holding AG EV-to-FCF Related Terms
Veraxa Biotech Holding AG EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG EV-to-FCF Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-FCF
0.00
0.00
0.00
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-FCF
0.00
0.00
0.00
0.00
0.00
VRXA vs TTRX, IRD, IFRX: EV-to-FCF Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's EV-to-FCF falls into.
Veraxa Biotech Holding AG's current Enterprise Value is $250.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veraxa Biotech Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a EV-to-FCF of -19.59 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 345 companies in the Biotechnology industry.
Is Veraxa Biotech Holding AG's EV-to-FCF too high?
Veraxa Biotech Holding AG's current EV-to-FCF is -19.59. Based on the distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 345 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's EV-to-FCF compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 345 companies for EV-to-FCF. This places Veraxa Biotech Holding AG in the lower half of its industry. The industry median EV-to-FCF is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Veraxa Biotech Holding AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current EV-to-FCF is -19.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current EV-to-FCF of -19.59. The current EV-to-FCF is -19.59. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current EV-to-FCF is -19.59 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
